Reddit Posts
Mentions
https://www.stocktitan.net/news/NXL/nexalin-technology-receives-nasdaq-listing-status-8m5zehb7tdz0.html
I’m in Australia so I trade a lot on the Aussie market (ASX), but also do a bit on the US market. Please do your own research on these companies and make your own call if you’re interested I’ve been selling off ASX: EOS on the recent rally, but now I’m look for opportunities to buy back in since I believe the company is very promising. They do anti-drone defence. It’s a bit too volatile right now to make a call, but give it some time, might have a clearer picture. EOS was my golden goose this year Recently bought in at $2 on ASX:NXL and doubled down at $2.70. Promising company, promising direction with investment in proprietary AI software solutions for existing business models. I still think the stock is in an attractive position, They also have great shareholder reports that are worth reading before buying the stock. ASX: NVX is hovering on a strong base of support. The company has very strong short term return if you can time it right. I was very close to buying, but missed the rally a couple weeks ago. Sitting on this one in case another opportunity comes With regard to US stocks I recently went long on EL. This is a bet the company and the industry. Consumer spending in this current and future economy will spend more on small ticket consumer items over big ticket. EL is at an attractive right price now, and seems like a good long term bet Been sitting on PRAA for a while. Again the price is currently very attractive, and seems to have successfully retested a base of support. I’ve made a partial purchase recently, which is already paying off. I think the industry (purchasing and reclaiming debt) could be lucrative medium term, but I’m generally not too interested in the sector or very inspired by the company. Also decided to fully cash out on my NVDA, and AMD stock. NVDA is too expensive for my taste, and I don’t understand well enough what is happening in AMD to cause the recent rally to be so big, so I decided to just take the win and leave. I’m staying long on intel (for now), and holding a partial position in Google. That sums up my takes over the last 3ish months for me.
I bought NXL at 1.87 am I cooked
Any thoughts on $NXL for AH?
Anyone have any NXL opinions?
NXL Announces Additional Positive Clinical Results in Alzheimer’s Disease with Gen-2 SYNC Neurostimulation Device
SPAI looks like a good play RUM - I'm staying away from media stocks (got burned more than 2x) NXL - added to watch list Thanks
Check out RUM, SPAI and NXL
I threw a bit into NXL after it was mentioned a little while ago. From the chart, it did just pass its mid-Jan peak and looks like it could potentially continue a bit of an upward trend.
Obviously BBAI is mooning on today’s news. I’m on NXL today. FDA approved product and digging into their SEC filings reveals several recent purchases by the CMO (chief medical officer). They’re not exactly massive but seems to be headed in the right direction as sales should start to take off this quarter. Bought another 500 shares this morning at $3.14. NFA
Any suggestion on KULR and NXL ?, I’m still new to the penny stock though.
Sure thing: ALGS: > Aligos Therapeutics, Inc. (ALGS) is currently trading at $19, showing a strong upward momentum with the RSI indicating overbought conditions across multiple timeframes, suggesting potential for a pullback. The MACD histogram is positive, reinforcing bullish sentiment, while the stock's recent surge above its 10-day SMA of $15.81 and 20-day EMA of $13.90 highlights strong buying pressure. Despite the lack of recent news or significant market interest, the technical indicators suggest a continuation of the uptrend, albeit with caution due to overbought signals. Given the broader market's cautious optimism, ALGS may experience moderate volatility. For today's session, consider a LONG position with an entry around $18.50, targeting $21.00 as the first price target and $23.00 as the second, with a stop loss at $17.00. Confidence in reaching the first target is moderate due to current momentum, while the second target carries lower confidence given potential resistance and market uncertainties. Keep an eye on broader market movements and any emerging news that could impact sentiment. MBLY: > Mobileye Global Inc. (MBLY) is showing signs of short-term bullish momentum, supported by a positive MACD histogram and RSI levels above 60, indicating potential upward movement. The stock's current price of $16.90 is above its 10-day SMA of $16.33, suggesting recent strength, while the broader market sentiment is cautiously optimistic, with technology sectors showing resilience. Recent partnerships and speculation about growth prospects in the autonomous driving sector add to the positive sentiment, although competition remains a concern. Given the high short interest, a short squeeze could further propel the stock upwards. For today's trading session, consider a long position with an entry around $16.80, targeting $17.20 as the first price target and $17.50 as the second, with a stop loss at $16.40 to manage risk. Confidence in reaching the first target is moderate due to mixed market signals, but the second target carries lower confidence given potential resistance and broader market uncertainties. Keep an eye on upcoming announcements and market conditions for any shifts in sentiment. CLDI > Calidi Biotherapeutics, Inc. (CLDI) is currently trading at $2.40, showing a strong upward momentum following its recent public offering priced at $1.69 per share, which raised $7.5 million for operational and R&D purposes. The stock's technical indicators are bullish, with the 10-day SMA at $2.08 and the 8-day EMA at $2.18, suggesting continued upward pressure. The RSI values around 60 indicate moderate buying strength without being overbought, while the MACD histogram supports a positive trend. Despite the lack of significant market sentiment or news, the successful capital raise and potential for future growth could attract investor interest. Given the broader market's cautious optimism, CLDI may experience moderate volatility but with an upward bias. For today's session, consider a long position with an entry around $2.35, targeting $2.60 as the first price target and $2.75 as the second, with a stop loss at $2.20. Confidence in reaching the first target is moderate due to recent positive developments, while the second target carries lower confidence given potential market fluctuations. BIVI: > BioVie Inc. (BIVI) is currently trading at $3.51, showing a strong upward momentum with the 10-day SMA at $3.08 and the 8-day EMA at $3.22, indicating a bullish trend. The RSI values are high, suggesting the stock is overbought, but the MACD histogram remains positive, supporting continued upward movement. Recent trading volumes have been significant, surpassing the 65-day average, which could indicate sustained interest despite the lack of specific news catalysts. Broader market sentiment is cautiously optimistic, with SPY and QQQ showing resilience, which may support BIVI's upward trajectory. Given these factors, a long position is recommended with an entry around $3.50, targeting $3.75 as the first price target and $4.00 as the second, with a stop loss at $3.30 to manage downside risk. Confidence in reaching the first target is moderate due to current momentum, while the second target carries lower confidence given potential resistance and broader market uncertainties. Investors should remain vigilant for any sudden changes in market conditions or unexpected news that could impact BIVI's performance. NXL: > Nexalin Technology, Inc. (NXL) is currently trading at $3.97 with a market cap of approximately $49.9 million and no significant news driving its movement. The stock has shown a strong upward trend recently, with the 10-day SMA at $3.73 and the 20-day EMA at $3.12, indicating bullish momentum. The RSI values are above 60, suggesting the stock is not yet overbought but is approaching that territory. The MACD histogram is positive, reinforcing the bullish sentiment. Given the broader market's cautious optimism and NXL's technical indicators, a long position could be considered. For today's session, an entry price around $3.95 is advisable, with a first target of $4.10 and a second target of $4.25, while setting a stop loss at $3.80 to manage risk. Confidence in reaching the first target is moderate due to the lack of volume and market interest, while the second target carries lower confidence unless new catalysts emerge.
NXL been going nuts lately
$NXL with movement in the pre-market. $HNST is also up in the pre-market. I hope others are enjoying this run as much as me. I'm up 20%. The exits have been put in place but keeping my fingers crossed that it keeps running like it is in Pamplona. 🐂
$NXL seems to have made a higher low. A push back into the $2.50 range would be a good profit. $CNTB seems to have support at the $1.20 - $1.25 range. I'll see if this holds and breaks the downtrend. $LSF may have created its higher low. Pre-market has it up. Maybe it makes another $1 move. I'm watching if it breaks the current bear trend line.
Just checked the actual column header: Short Sale Borrowing Rate(%) $NXL tops the list at 735%. $GDHG is on the list too, at 30.75% ***so, what is going on here?
I think this is about short squeezes? I just checked NXL on Ortex, it says 18.5% short interest. Don't know what is going on there, but, correct me if I'm wrong, it doesn't sound like a candidate for this sub, e.g. a short squeeze for me.
Why does $NXL have an over 700% borrow margin % then when looking at a ToS scanner?
FAANG MAANG GAANG and all their nieces/nephews/relatives. Try KALA, VLCN, FFIE, CMND, NXL, FFIE for next week. Got my GME & DJT options ready!
NXL this one looks promising, especially with the current secondary IPO offering pending.
NXL - Nexalin Technology - Since last week I have been putting some dollars into this company, it is a kind tech/health company, in its words: > Recently they appointed a kind of lobbyist on its board that could make it easier to get Gov contracts. It has grown from $1.47 to $2.36. Also, they have announced positive results of a clinical study in one of its products. Right now it has $18.00M of market cap, it could be a potential candidate for an acquisition by a big company either pharmaceutical or technological. I plan to put 1 paycheck in this. [https://www.globenewswire.com/news-release/2024/04/02/2855956/0/en/Nexalin-Technology-Announces-the-Appointment-of-Government-Affairs-Veteran-William-A-Hudson-Jr-to-Military-Government-Advisory-Board.html](https://www.globenewswire.com/news-release/2024/04/02/2855956/0/en/Nexalin-Technology-Announces-the-Appointment-of-Government-Affairs-Veteran-William-A-Hudson-Jr-to-Military-Government-Advisory-Board.html) [https://nexalin.com/investors/](https://nexalin.com/investors/)
Only available for selling, same goes for NXL.
anybody know why NXL is shooting up so much? 411% past 5 days
$NXL went up 100% today
NXL up 30% to ~ $1 News (3 hrs ago): Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego https://www.globenewswire.com/news-release/2024/03/28/2854008/0/en/Nexalin-Technology-Announces-Positive-Results-of-Clinical-Study-Validating-its-Gen-2-tACS-Device-for-Reducing-Pain-Among-Veterans-with-Mild-Traumatic-Brain-Injury-at-University-of-.html
CNBC just has a commercial about NXL, the stock pumped right after the commercial. Looks like a good one to buy now